Compare CASY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CASY | INCY |
|---|---|---|
| Founded | 1959 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.0B | 17.0B |
| IPO Year | N/A | 1993 |
| Metric | CASY | INCY |
|---|---|---|
| Price | $571.40 | $104.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $565.78 | $90.71 |
| AVG Volume (30 Days) | 294.4K | ★ 2.3M |
| Earning Date | 12-09-2025 | 10-28-2025 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | 13.46 | ★ 3878.02 |
| EPS | ★ 15.58 | 5.90 |
| Revenue | ★ $16,410,268,000.00 | $4,813,105,000.00 |
| Revenue This Year | $10.98 | $19.33 |
| Revenue Next Year | $6.01 | $10.47 |
| P/E Ratio | $36.61 | ★ $17.70 |
| Revenue Growth | 8.74 | ★ 18.09 |
| 52 Week Low | $372.09 | $53.56 |
| 52 Week High | $573.76 | $109.28 |
| Indicator | CASY | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 62.65 | 62.26 |
| Support Level | $539.51 | $100.30 |
| Resistance Level | $564.61 | $107.61 |
| Average True Range (ATR) | 12.75 | 3.01 |
| MACD | 4.10 | -0.57 |
| Stochastic Oscillator | 95.95 | 49.03 |
Casey's General Stores Inc serves as convenience store chain with its 2,900 locations, positioned in the Midwest United States. About half of Casey's stores are located in rural towns with populations under 5,000. While fueling stations serve as a key traffic driver, about two-thirds of the company's gross profit stems from in-store sales of grocery items, prepared meals, and general merchandise. Casey's owns more than 90% of its stores and operates the majority of its warehousing and distribution processes internally.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.